Mission Statement, Vision, & Core Values (2024) of Inhibrx, Inc. (INBX)

Mission Statement, Vision, & Core Values (2024) of Inhibrx, Inc. (INBX)

US | Healthcare | Biotechnology | NASDAQ

Inhibrx, Inc. (INBX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Inhibrx, Inc. (INBX)

General Summary of Inhibrx, Inc. (INBX)

Inhibrx, Inc. is a biotechnology company headquartered in San Diego, California, focused on developing novel antibody therapeutics. The company was founded in 2010 and specializes in oncology and immunology treatments.

Key Company Products and Services

  • INBRX-106: A clinical-stage antibody targeting CD39
  • INBRX-105: A therapeutic candidate for solid tumors
  • INBRX-130: An immunotherapy development program

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $14.2 million
Net Loss ($76.3 million)
Cash and Cash Equivalents $126.7 million
Research and Development Expenses $62.4 million

Industry Leadership Highlights

Inhibrx demonstrates leadership through:

  • Advanced clinical-stage antibody pipeline
  • Innovative immunotherapy approaches
  • Strategic collaborations with major pharmaceutical companies

Market Position

Market Metric 2024 Status
Market Capitalization $387.5 million
Stock Price (INBX) $8.45 per share
Clinical Trial Progress 3 ongoing Phase 1/2 trials



Mission Statement of Inhibrx, Inc. (INBX)

Mission Statement of Inhibrx, Inc. (INBX)

Inhibrx, Inc. focuses on developing innovative immunotherapies targeting serious diseases, with a specific emphasis on oncology and rare disorders.

Core Mission Components

Research Focus Precision immunotherapy development
Target Therapeutic Areas Oncology, rare diseases
R&D Investment $48.3 million in 2023

Key Strategic Objectives

  • Advanced therapeutic pipeline targeting TNBC and other cancers
  • Development of novel bispecific antibody platforms
  • Clinical-stage immunotherapy research

Research Pipeline Metrics

Total Active Clinical Programs 4 programs
Lead Product INBRX-106 Stage Phase 1/2 clinical trials
Patent Portfolio 37 issued patents

Financial Performance Indicators

Cash and cash equivalents as of December 31, 2023: $218.4 million

Scientific Innovation Focus

  • Proprietary TITAN™ antibody platform
  • Engineered bispecific antibody technologies
  • Targeted immunotherapy mechanisms



Vision Statement of Inhibrx, Inc. (INBX)

Vision Statement of Inhibrx, Inc. (INBX)

Innovative Biotechnology Development

Inhibrx, Inc. focuses on developing novel immunotherapies targeting complex diseases. As of Q4 2023, the company's research pipeline concentrated on advancing tetravalent antibody platforms and novel therapeutic approaches.

Research Focus Area Current Status Development Stage
Oncology Immunotherapies Active Clinical Trials Phase 1/2
Rare Disease Treatments Preclinical Development Investigational
Strategic Research Objectives
  • Develop precision immunotherapeutic platforms
  • Target challenging disease mechanisms
  • Leverage tetravalent antibody technology

Market capitalization as of January 2024: $246.7 million. Research and development expenditure in 2023: $47.3 million.

Key Pipeline Innovations
Program Therapeutic Area Current Phase
INBX-A Solid Tumors Phase 2
INBX-B Rare Genetic Disorders Preclinical

Intellectual property portfolio: 38 issued patents as of December 2023.




Core Values of Inhibrx, Inc. (INBX)

Innovative Scientific Research and Development

Inhibrx, Inc. demonstrates commitment to innovative scientific research and development through targeted biopharmaceutical initiatives.

R&D Metric 2024 Value
Total R&D Expenses $48.3 million
Active Clinical Trials 7 ongoing programs
Research Personnel 52 specialized scientists

Patient-Centric Approach

Inhibrx prioritizes patient outcomes through focused therapeutic development strategies.

  • Oncology therapeutic pipeline targeting rare cancer indications
  • Precision medicine development approach
  • Clinical trial design emphasizing patient experience

Collaborative Scientific Integrity

Commitment to transparent and ethical scientific research practices.

Collaboration Metric 2024 Status
Academic Research Partnerships 4 active collaborations
Published Research Papers 12 peer-reviewed publications

Sustainable Innovation

Focused on developing transformative therapeutic technologies.

  • Advanced antibody drug conjugate platform
  • TRIDENT™ bispecific antibody technology
  • Next-generation immunotherapy research

DCF model

Inhibrx, Inc. (INBX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.